RESMED INC
Last 30 daysNo qualifying insider buying. Sales: $1.11M by 1 insider.
Showing the first 6 of 17 trades on this page.
Chief Product Officer
ResMed Common Stock
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Global General Counsel
ResMed Common Stock
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Chairman and CEO
ResMed Common Stock
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Chief Financial Officer
ResMed Common Stock
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Chairman and CEO
ResMed Common Stock
Chairman and CEO
ResMed Common Stock Options
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
Chairman and CEO
ResMed Common Stock
Chairman and CEO
ResMed Common Stock Options
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
Chairman and CEO
ResMed Common Stock
Chairman and CEO
ResMed Common Stock Options
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
Chairman and CEO
ResMed Common Stock
Chairman and CEO
ResMed Common Stock Options
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
Global General Counsel
ResMed Common Stock
Chairman and CEO
ResMed Common Stock
Chairman and CEO
ResMed Common Stock Options
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
Chairman and CEO
ResMed Common Stock
Chairman and CEO
ResMed Common Stock Options
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
| Reporting insider | Security / transaction | Amount / price | Value | Traded / disclosed | Source |
|---|---|---|---|---|---|
| Chief Product Officer | ResMed Common StockGrant or award | 6,461Award · no purchase price | Non-cash award | Aug 14Filed Oct 1 · 48d later | SEC filing |
| Global General Counsel | ResMed Common StockGrant or award | 3,230Award · no purchase price | Non-cash award | Aug 14Filed Oct 1 · 48d later | SEC filing |
| Chairman and CEO | ResMed Common StockGrant or award | 13,547Award · no purchase price | Non-cash award | Aug 14Filed Oct 1 · 48d later | SEC filing |
| Chief Financial Officer | ResMed Common StockGrant or award | 9,072Award · no purchase price | Non-cash award | Aug 14Filed Oct 1 · 48d later | SEC filing |
| Chairman and CEO | ResMed Common StockOption exercise or conversion10b5-1 | 4,991$146.34 / share | $730.38K | Sep 8Filed Sep 10 · 2d later | SEC filing |
| Chairman and CEO | ResMed Common Stock OptionsOption exercise or conversion10b5-1 | Derivative units4,991$146.34 exercise / conversion price | Not a separate purchase | Sep 8Filed Sep 10 · 2d later | SEC filing |
| Chairman and CEO | ResMed Common StockOption exercise or conversion10b5-1 | 4,991$146.34 / share | $730.38K | Aug 7Filed Aug 11 · 4d later | SEC filing |
| Chairman and CEO | ResMed Common Stock OptionsOption exercise or conversion10b5-1 | Derivative units4,991$146.34 exercise / conversion price | Not a separate purchase | Aug 7Filed Aug 11 · 4d later | SEC filing |
| Chairman and CEO | ResMed Common StockOption exercise or conversion10b5-1 | 4,991$146.34 / share | $730.38K | Jul 7Filed Jul 9 · 2d later | SEC filing |
| Chairman and CEO | ResMed Common Stock OptionsOption exercise or conversion10b5-1 | Derivative units4,991$146.34 exercise / conversion price | Not a separate purchase | Jul 7Filed Jul 9 · 2d later | SEC filing |
| Chairman and CEO | ResMed Common StockOption exercise or conversion10b5-1 | 4,991$146.34 / share | $730.38K | Jun 8Filed Jun 9 · 1d later | SEC filing |
| Chairman and CEO | ResMed Common Stock OptionsOption exercise or conversion10b5-1 | Derivative units4,991$146.34 exercise / conversion price | Not a separate purchase | Jun 8Filed Jun 9 · 1d later | SEC filing |
| Global General Counsel | ResMed Common StockExercise-price or tax withholding | 269$190.57 / share | $51.21K | Jun 1Filed Jun 3 · 2d later | SEC filing |
| Chairman and CEO | ResMed Common StockOption exercise or conversion10b5-1 | 4,991$146.34 / share | $730.38K | May 7Filed May 11 · 4d later | SEC filing |
| Chairman and CEO | ResMed Common Stock OptionsOption exercise or conversion10b5-1 | Derivative units4,991$146.34 exercise / conversion price | Not a separate purchase | May 7Filed May 11 · 4d later | SEC filing |
| Chairman and CEO | ResMed Common StockOption exercise or conversion10b5-1 | 4,991$146.34 / share | $730.38K | Apr 7Filed Apr 9 · 2d later | SEC filing |
| Chairman and CEO | ResMed Common Stock OptionsOption exercise or conversion10b5-1 | Derivative units4,991$146.34 exercise / conversion price | Not a separate purchase | Apr 7Filed Apr 9 · 2d later | SEC filing |
ResMed Inc. Common Stock · Stock
The filing reports a full sale for a joint account.
Thomas H TubervilleReporting Senate memberResMed Inc. Common Stock · Stock
The filing reports a purchase for the member.
No eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.
